GutCRINE

GutCRINE is a private preclinical biotech spinout from the University of Copenhagen developing a new class of microbiome-derived biological medicines it calls pharmabiotics. The company is based on discoveries that human gut bacteria can produce hormone-like polypeptides that regulate host metabolism, appetite, glucose control, and bone biology. Its lead scientific programs center on RORDEP-producing bacteria and RORDEP proteins, which have shown effects on body weight, blood sugar, and bone density in preclinical models. GutCRINE is focused primarily on cardiometabolic and age-related diseases, including obesity, type 2 diabetes, osteoporosis, and potentially neurodegenerative disorders. The company appears to be venture-backed by Eir Ventures and UCPH Ventures and remains privately held.